Walmart to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Screening Test
October 19 2021 - 6:39AM
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that
Walmart has begun in-store sales and rollout of the Company’s EZ
Detect™ colorectal disease screening test within the nationwide
Walmart retail system. Biomerica has shipped the EZ Detect product
to Walmart distribution centers in the US and product is projected
to be on the shelf in over 4,600 Walmart Stores nationwide over the
next two weeks. The in-store retail placement follows Biomerica’s
previous announcement in early October, that Walmart had begun
sales of EZ Detect™ product for online purchase through Walmart.com
(https://www.walmart.com/ip/EZ-Detect-Colon-Disease-Test-Kit/577079744).
As part of its ongoing sales strategy, the Company has hired an
internal digital and social media team to increase its presence on
all major social communication platforms (Instagram:
https://bit.ly/3j5FYDB; Facebook:
https://bit.ly/3aBJBfN; Twitter:
https://bit.ly/3BNROJW), and to promote awareness for its at-home
testing products. In addition, Biomerica is in negotiations with
several large partners for distribution of the EZ Detect™ product
in Asia, Europe and the Middle East.
The EZ Detect™ colon disease screening test is
the simplest at-home test to detect occult (hidden) blood in a
person’s stool, which can be an early warning sign of colorectal
diseases, including colon and rectal cancers. The test does not
require handling of stool or dietary restrictions. A person
simply places an EZ Detect™ test pad into the toilet after a bowel
movement. A change in the pad’s color to blue/green, which
would appear within two minutes, indicates the presence of blood in
the stool. The pad is then simply flushed down the
toilet.
“We’re excited to broaden our relationship with
Walmart to now have EZ Detect™ available in the store at retail
locations across the country, in addition to their online sales
channel,” commented Zack Irani, CEO of Biomerica. “Walmart is the
largest retailer in the world. Each week, approximately 220 million
customers and members visit stores and clubs in 24 countries and on
eCommerce websites. Early detection is a key factor to beating
colorectal cancer. The inclusion of EZ Detect™ on Walmart shelves
is a significant development in making our easy and innovative
in-home tests available to more patients.”
Colorectal cancer (“CRC”) is the second most
common cause of cancer death in the United States. In 2020, an
estimated 147,950 Americans were projected to be diagnosed with
CRC, and an estimated 53,200 were projected to die from the
disease, including 17,930 cases and 3,640 deaths in individuals
under the age of 50 [1].
In a study performed by Johns Hopkins
University, EZ Detect™ was preferred 10:1 by patients over another
fecal occult blood test. Published studies have also indicated that
the best colorectal screening test is “the one that gets done.” [2]
Other colorectal screening tests require handling of the stool and
delivering or mailing the stool sample to a lab for processing.
Handling of the stool results in a high percentage of these
competing tests never being performed by patients[3]. EZ Detect™
does not require handling of the stool, is simple to perform and
provides results at home in just two minutes.
For further information about the EZ Detect
Product, please visit ezdetect.com
About Biomerica (NASDAQ:
BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical
technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point of
care (in home and in physicians' offices) and in hospital/clinical
laboratories for detection and/or treatment of medical conditions
and diseases. The Company's products are designed to enhance the
health and well-being of people, while reducing total healthcare
costs. Biomerica’s primary focus is on gastrointestinal and
inflammatory diseases where the Company has multiple diagnostic and
therapeutic products in development.
1. Siegel, R.L., et al.,
Colorectal cancer statistics, 2020. CA Cancer J Clin, 2020.
70(3): p.
145-164.2. Lansdorp-Vogelaar,
I., A.B. Knudsen, and H. Brenner, Cost-effectiveness of colorectal
cancer screening - an overview. Best Pract Res Clin Gastroenterol,
2010. 24(4): p.
439-49.3. Navarro, M., et al.,
Colorectal cancer population screening programs worldwide in 2016:
An update. World J Gastroenterol, 2017. 23(20): p.
3632-3642.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to the efficacy of the Company’s EZ Detect and
other tests, FDA clearance of the Company’s products, possible
in-store offering of EZ Detect, the number of stores where the EZ
Detect and other products are or will be sold or available, the
rapidity of testing results, negotiations with existing and new
international distribution partners, uniqueness of the Company’s
products, test result accuracy of products, potential for the
products to detect signs of cancer and other diseases, pricing of
the Company’s test kits, demand for domestic or international
orders, potential revenues from the sale of current or future
products, availability of the Company’s test kits, and patent
protection on any of the Company’s products or technologies. Such
forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results
in the future, including, without limitation: results of studies
testing the efficacy of the Company’s tests, InFoods tests and
other products; regulatory approvals necessary prior to
commercialization of the Company’s products; availability of the
Company’s test kits and other products; capacity, resource and
other constraints on our suppliers; dependence on our third party
manufacturers; dependence on international shipping carriers;
governmental import/export regulations; demand for our various
tests and other products; competition from other similar products
and from competitors that have significantly more financial and
other resources available to them; governmental virus control
regulations that make it difficult or impossible for the company to
maintain current operations; the Company’s ability to comply with
current and future regulations in the countries where our products
are made and sold and the Company’s ability to obtain patent
protection on any aspects of its rapid test technologies.
Accordingly, such results may differ materially from those
expressed in any forward-looking statements made by or on behalf of
Biomerica. Additionally, potential risks and uncertainties include,
among others, fluctuations in the Company's operating results due
to its business model and expansion plans, downturns in
international and or national economies, the Company's ability to
raise additional capital, the competitive environment in which the
Company will be competing, and the Company's dependence on
strategic relationships. The Company is under no obligation to
update any forward-looking statements after the date of this
release.
Corporate Contact:
John Nesbett /Jennifer BelodeauIMS Investor
Relations203.972.9200jnesbett@institutionalms.com
Source: Biomerica, Inc.
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2023 to Apr 2024